Table 1 Characteristics of the study participants according to WWI quartiles.
Variables | Weight-adjusted waist index (cm/√kg) | P-value | |||
|---|---|---|---|---|---|
Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | ||
(≤ 9.14) | (9.15–9.93) | (9.94–10.79) | (≥ 10.80) | ||
Participants, N | 1235 | 1229 | 1243 | 1255 | |
Age, years | 66.70 ± 4.78 | 66.30 ± 4.51 | 66.23 ± 4.71 | 66.32 ± 4.70 | 0.059 |
Male, % | 633 (51.26%) | 639 (51.99%) | 628 (50.52%) | 675 (53.78%) | 0.401 |
Current smoker, % | 357 (28.91%) | 351 (28.56%) | 370 (29.77%) | 389 (31.00%) | 0.55 |
Current drinker, % | 304 (24.62%) | 315 (25.63%) | 339 (27.27%) | 344 (27.41%) | 0.322 |
Heart rate, bpm | 79.93 ± 9.73 | 80.40 ± 9.66 | 80.11 ± 9.81 | 80.53 ± 9.91 | 0.409 |
SBP, mmHg | 142.51 ± 19.06 | 143.42 ± 20.14 | 143.65 ± 20.31 | 143.62 ± 20.14 | 0.447 |
DBP, mmHg | 87.36 ± 13.41 | 88.63 ± 14.05 | 88.80 ± 14.29 | 89.37 ± 13.90 | 0.003 |
WC, cm | 77.30 ± 5.76 | 84.49 ± 5.57 | 88.20 ± 5.65 | 92.78 ± 5.49 | < 0.001 |
BMI, kg/m2 | 22.37 ± 2.76 | 24.03 ± 3.12 | 24.93 ± 3.10 | 25.93 ± 2.87 | < 0.001 |
Comorbidities, % | |||||
Dyslipidemia | 750 (60.73%) | 748 (60.86%) | 747 (60.10%) | 761 (60.64%) | 0.981 |
Atrial fibrillation | 31 (2.51%) | 34 (2.77%) | 26 (2.09%) | 19 (1.51%) | 0.161 |
Charlson comorbidity index | 0.100 | ||||
0 | 562 (45.51%) | 504 (41.01%) | 520 (41.83%) | 507 (40.40%) | |
1 | 339 (27.45%) | 356 (28.97%) | 371 (29.85%) | 354 (28.21%) | |
≥ 2 | 334 (27.04%) | 369 (30.02%) | 352 (28.32%) | 394 (31.39%) | |
Coronary heart disease | 210 (17.00%) | 190 (15.46%) | 221 (17.78%) | 207 (16.49%) | 0.471 |
Diabetes | 306 (24.78%) | 334 (27.18%) | 340 (27.35%) | 353 (28.13%) | 0.265 |
Hypertension duration, years | 0.172 | ||||
< 5 | 341 (27.61%) | 318 (25.87%) | 351 (28.24%) | 310 (24.70%) | |
≥ 5 | 894 (72.39%) | 911 (74.13%) | 892 (71.76%) | 945 (75.30%) | |
Laboratory parameters | |||||
UA, µmol/L | 319.24 ± 87.94 | 331.48 ± 88.94 | 337.35 ± 88.23 | 345.74 ± 94.73 | < 0.001 |
eGFR, mL/min per 1.73 m2 | 84.24 ± 15.43 | 82.62 ± 15.61 | 80.70 ± 14.86 | 78.96 ± 14.83 | < 0.001 |
TC, mmol/L | 4.54 ± 0.98 | 4.50 ± 0.95 | 4.50 ± 0.96 | 4.46 ± 0.97 | 0.258 |
TG, mmol/L | 1.77 ± 1.10 | 1.81 ± 1.08 | 1.91 ± 1.12 | 2.00 ± 1.16 | < 0.001 |
HDL-C, mmol/L | 1.11 ± 0.26 | 1.08 ± 0.27 | 1.05 ± 0.26 | 1.02 ± 0.25 | < 0.001 |
LDL-C, mmol/L | 2.80 ± 0.82 | 2.82 ± 0.80 | 2.84 ± 0.84 | 2.88 ± 0.84 | 0.105 |
FPG, mmol/L | 5.08 ± 1.21 | 5.14 ± 1.28 | 5.13 ± 1.22 | 5.26 ± 1.29 | 0.002 |
Hcy, µmol/L | 15.16 ± 6.43 | 15.13 ± 6.45 | 14.88 ± 6.23 | 15.36 ± 6.20 | 0.300 |
hs-CRP, mg/L | 2.67 ± 2.72 | 2.97 ± 2.84 | 2.89 ± 2.93 | 2.97 ± 2.98 | 0.027 |
Concomitant medications, % | |||||
Aspirin | 812 (65.75%) | 815 (66.31%) | 867 (69.75%) | 832 (66.29%) | 0.129 |
Statins | 561 (45.43%) | 552 (44.91%) | 579 (46.58%) | 572 (45.58%) | 0.866 |
ACEI/ARB | 854 (69.15%) | 833 (67.78%) | 875 (70.39%) | 869 (69.24%) | 0.574 |
Beta-blocker | 425 (34.41%) | 423 (34.42%) | 457 (36.77%) | 459 (36.57%) | 0.430 |
Calcium channel blockers | 978 (79.19%) | 952 (77.46%) | 985 (79.24%) | 1002 (79.84%) | 0.504 |
Diuretics | 285 (23.08%) | 294 (23.92%) | 275 (22.12%) | 275 (21.91%) | 0.612 |
Insulin | 69 (5.59%) | 79 (6.43%) | 126 (10.14%) | 114 (9.08%) | < 0.001 |
Oral antidiabetic agents | 196 (15.87%) | 209 (17.01%) | 219 (17.62%) | 225 (17.93%) | 0.539 |
